InsideArbitrage Event Driven Monitor – October 24, 2024

Merger Arbitrage

1. LUMO: The acquisition of Lumos Pharma, Inc. (LUMO) by Double Point Ventures LLC, for a closing value of $38 million. Under the terms of the agreement, Double Point Ventures will acquire Lumos Pharma’s outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right (CVR) per share, with potential future cash payments based on LUM-201 sales milestones through 2037, business transactions, or agreements involving Lumos Pharma’s legacy products within 18 months.
2. CTLT: Reuters reported that the CEO of Roche has urged authorities to block the takeover of Catalent (CTLT) by Novo Nordisk (NVO), citing harm to industry peers.
3. ITI: Shareholders of Iteris (ITI) approved the company’s merger with Almaviva at a special meeting of shareholders held on October 22.

You can check out new deals, all deal updates, and spreads on active deals in our Merger Arbitrage Tool for premium members here.

Only plus or premium subscribers can access this post. Subscribe today.